Metabolic diseases such as type 2 diabetes, fatty liver disease and cardiovascular disease represent one of the defining health challenges of the twenty-first century, and obesity sits at the center of that epidemic. Fat tissue in obesity is not metabolically inert; it is chronically inflamed, packed with neutrophils, macrophages, B cells and T cells whose interactions with adipocytes shape systemic insulin sensitivity. Among these immune players, regulatory T cells, or Tregs, have emerged as decisive guardians of fat tissue homeostasis. Visceral adipose tissue in lean mammals harbors a distinctive population of Tregs with transcriptional profiles and antigen receptor repertoires unlike those of lymphoid tissue Tregs. When these cells are experimentally depleted in living animals, adipose inflammation worsens and metabolic parameters deteriorate, with blood glucose rising and insulin sensitivity falling. Human studies mirror this picture: visceral fat Tregs are diminished in obesity and are important for maintaining glucose tolerance.

The problem has always been access. T cells resident in fat tissue can be isolated only in very low numbers from fat depots, making functional analysis of how they interact with adipocytes extraordinarily difficult. A team led by Christian Kühne and Kim Ohl at RWTH Aachen University set out to solve this by expanding an ex vivo adipose tissue organoid system the group had previously shown to be suitable for immunometabolic studies. Those earlier organoids contained mature adipocytes and some immune cells, mostly macrophages and eosinophils, but no T cells. The new work closes that gap by adding splenocytes from donor mice to fully differentiated fat organoids and letting the T cells migrate in on their own.

The protocol takes twenty days from tissue harvest to T cell-containing organoids. Stromal vascular fraction cells are first isolated from visceral fat surrounding the testes or subcutaneous fat from the inguinal region of lean male C57BL/6 mice, digested with collagenase, and briefly pre-cultured in two dimensions. The cells are then seeded at 50,000 cells per well into ultra-low attachment, U-bottom 96-well plates, where they self-assemble into spheroids within roughly three days. Adipocyte differentiation is driven by a classic cocktail of insulin, dexamethasone, rosiglitazone and IBMX, along with the thyroid hormone T3 and supporting micronutrients such as ascorbic acid, biotin and pantothenic acid. After eight days of induction and differentiation, the resulting organoids are mature adipocyte-rich spheroids ready for co-culture. One million freshly isolated splenocytes are then added to each well, and over the next two days T cells actively infiltrate the organoids.

Flow cytometry, the workhorse of the analysis, revealed a striking depot-specific pattern. When splenocytes were co-cultured with organoids made from visceral fat, CD45-positive CD3-positive T cells were readily detected inside the spheroids. Organoids derived from subcutaneous fat, by contrast, remained essentially T cell-free under unstimulated conditions. Even more intriguing, the T cells that entered visceral fat organoids contained a markedly higher proportion of FOXP3-positive Tregs, tracked with a red fluorescent reporter, than the T cells remaining in the surrounding supernatant. This suggests that visceral fat organoids preferentially recruit the regulatory subset, recapitulating the Treg-rich milieu of lean visceral fat in vivo. The infiltrating cells also showed elevated CD69 expression, although only about ten percent of them carried this early activation marker, indicating that most infiltrating T cells remain in a quiescent, tissue-resident-like state. The data further suggested that the infiltrating cells were predominantly CD4-positive, while CD8-positive cells largely stayed behind in the supernatant.

The researchers then asked what happens when the system is pushed into an inflammatory state, mimicking the conditions of obese adipose tissue. A one-hour pulse of lipopolysaccharide, or LPS, the cell wall component of E. coli that activates the innate immune receptor Toll-like receptor 4, transformed the behavior of both organoid types. Subcutaneous fat organoids, which had previously refused T cell entry, now became infiltrable, recruiting CD4-positive T cells at measurable rates. Visceral organoids showed a further, more modest increase in T cell entry. Crucially, the quality of the infiltrate differed: LPS-stimulated subcutaneous organoids contained significantly lower frequencies of Tregs than their visceral counterparts, implying that inflammation preferentially pulls in effector T cells rather than regulatory ones. This mirrors the in vivo shift, well documented in obesity research, in which CD4-positive effector T cells convert the anti-inflammatory atmosphere of lean visceral fat into a pro-inflammatory environment.

Cytokine measurements reinforced the physiological relevance of the model. Interleukin-6 secretion from visceral organoids tended to rise when splenocytes were present and climbed further after LPS stimulation, while tumor necrosis factor-alpha, a key inflammatory mediator in obese adipose tissue, increased significantly in LPS-stimulated co-cultures. The authors propose a mechanistic framework grounded in prior literature: LPS activates TLR4 on adipocytes, adipose stem cells and macrophages within the organoids, prompting the secretion of TNF-alpha and IL-6. TNF-alpha in turn induces adipose stem cells to express the chemokine CCL5, which signals through the receptor CCR5 on T cells and draws them into the tissue. Exactly how adipocyte activation orchestrates T cell migration, and why Tregs and effector T cells respond differently, are questions the team plans to pursue in this system.

The model’s design makes it unusually flexible. Because the T cells are supplied externally from splenocytes, they can be harvested from any of the vast catalogue of genetically engineered mouse strains, allowing researchers to test the effects of gene overexpression, knockdown or deficiency in the context of intact fat tissue. Drug compounds can be added directly to the culture to screen for therapeutic candidates. Standard downstream assays, including histology, flow cytometry, RNA analysis and cytokine enzyme-linked immunosorbent assays, all work with the organoids. The team also notes that human subcutaneous fat organoids have recently been generated by similar self-organization approaches, raising the prospect of a human version of this immune-fat co-culture platform built from donor material.

The authors are candid about the system’s current limits. Each organoid starts from only 50,000 stromal cells, so multiple spheroids must be pooled to harvest enough material for molecular analysis, and the excess of splenocytes in the co-culture does not perfectly reflect physiological cell ratios. The work has so far been performed exclusively with cells from male mice, even though recent studies show that visceral fat Tregs carry sex-specific gene expression programs and that two distinct Treg populations shape systemic metabolism, making replication in female mice a clear priority. LPS is also a somewhat blunt instrument for inducing inflammation, and the team intends to test more physiological stimuli such as TNF-alpha and interleukin-1 beta. Enzymatic digestion before flow cytometry can also perturb surface markers like CD4 and CD8, a technical wrinkle the group hopes to mitigate with gentler protocols and intracellular staining.

Even with these caveats, the advance addresses a genuine bottleneck. Visceral fat Tregs are rare, depot-restricted and notoriously difficult to study, yet they sit at the fulcrum of the relationship between obesity, inflammation and insulin resistance. Recent work has shown, for example, that cholesterol homeostasis is a key metabolic pathway for visceral Treg accumulation and that its disruption may explain Treg loss in obese humans and mice, a finding that could now be interrogated directly in the organoid system. A reproducible dish-based model in which fat tissue actively recruits its characteristic immune residents opens the door to mechanistic studies of T cell differentiation and migration into fat, dissection of Treg function in adipose inflammation and insulin resistance, and drug screening for new therapies targeting the immune-fat axis. In an era when metabolic disease strains health systems worldwide, a twenty-day recipe for growing immunologically complete fat tissue in a 96-well plate may prove to be a quietly powerful tool.

Autophagy, a critical intracellular degradation system, facilitates the recycling of damaged organelles and proteins, thus maintaining cellular homeostasis under stress conditions. The novel insights presented by Piletic and colleagues highlight autophagy not merely as a survival mechanism but as an active modulator of pathological fibrosis in adipose tissues during obesity. Their research demonstrates that autophagic processes exert control over purine nucleoside signalling, a biochemical pathway involved in cellular communication and metabolic regulation, to mitigate the fibrotic responses that typically escalate in obese states.

This revelation aligns with the increasingly recognized complexity of autophagy beyond its canonical housekeeping functions. Specifically, the study elucidates how autophagy-mediated regulation of purine nucleosides, such as adenosine and inosine, influences fibroblast activation and extracellular matrix (ECM) deposition. In obesity, uncontrolled fibroblast activity leads to ECM overproduction, resulting in stiffness and loss of tissue elasticity. By harnessing autophagy, cells can constrain this over-activation, preventing the pathological remodeling that underpins fibrosis.

A particularly striking aspect of this research is the identification of autophagy as a signaling nexus that balances metabolic cues with fibrotic pathways. Purine nucleosides are known to function as extracellular signaling molecules that modulate immune responses and tissue repair. Piletic et al. provide evidence that disrupting autophagy perturbs purine nucleoside metabolism, amplifying fibrotic signals and exacerbating tissue damage in obese adipose tissue. This interplay underscores the therapeutic potential of targeting autophagy pathways to modulate fibrosis without compromising essential metabolic functions.

To elucidate these mechanisms, the researchers employed sophisticated molecular and genetic tools in murine models of diet-induced obesity. By selectively impairing autophagy within adipose tissue, they observed a marked increase in fibrosis markers and dysfunctional purine nucleoside profiles. Conversely, enhancing autophagic flux restored purine metabolism balance and curtailed fibrotic progression. These findings offer compelling causal links rather than correlative associations, setting a new benchmark for fibrosis research in metabolic diseases.

Moreover, the study delves into the cellular heterogeneity within adipose tissue, revealing that autophagy’s antifibrotic effects are mediated predominantly through its action in adipocytes and resident immune cells. This cell-specific modulation of purine nucleoside signalling orchestrates a finely tuned response to metabolic stress, limiting the chronic inflammation that drives fibrosis. This highlights an emerging paradigm where intracellular degradative pathways directly shape extracellular signaling milieus to maintain tissue integrity.

In addition to its implications for obesity, the regulatory axis described could have broad relevance to other fibrotic pathologies, including liver cirrhosis, pulmonary fibrosis, and cardiac fibrosis, where purinergic signalling and autophagic dysfunctions are implicated. By delineating the molecular choreography linking autophagy to purine metabolism and fibrotic control, this work provides a conceptual framework translatable across multiple organ systems and disease states.

Importantly, the identification of purine nucleoside signalling as a downstream effector controlled by autophagy opens new therapeutic targeting strategies. Pharmacological agents capable of modulating autophagic pathways or purinergic receptors hold promise for curbing fibrosis while preserving or even enhancing beneficial metabolic and immunological functions. This could lead to more precise interventions with fewer off-target effects compared to current antifibrotic agents, which often lack tissue specificity.

The research also raises intriguing questions about the temporal dynamics of autophagy in metabolic tissues. Does the modulation of purine nucleoside signalling by autophagy act predominantly during early or advanced stages of obesity? The authors suggest that maintaining robust autophagy could be pivotal in early intervention to halt fibrosis before irreversible tissue damage occurs. Understanding these temporal relationships will be crucial in designing therapies that are both effective and appropriately targeted according to disease progression.

Adding a systems biology perspective, Piletic et al. integrated transcriptomic, metabolomic, and functional assays to create a comprehensive map of autophagy’s impact on purine metabolism and fibrosis. This multi-layered approach strengthens the causal narrative and highlights the complexity of metabolic-immune-fibrotic interactions. Future research building on this integrative model may uncover additional regulatory nodes and feedback loops critical for tissue homeostasis in obesity.

Furthermore, the study underscores the potential of autophagy-related biomarkers in predicting fibrosis risk and therapeutic responses in obese patients. Purine nucleoside levels in plasma or tissue biopsies might serve as accessible indicators of fibrotic status and autophagic activity, facilitating personalized medicine approaches. Developing such biomarkers would significantly enhance clinical management and monitoring of obesity-associated fibrotic diseases.

With obesity a major contributor to global health burden, the translational potential of these findings is profound. By harnessing the body’s intrinsic cellular recycling pathways, therapies emerging from this research could mitigate some of the most debilitating complications of obesity, including fibrotic organ failure. This offers hope for improved quality of life and reduced mortality among obese populations worldwide.

In sum, the discovery that autophagy functions as a molecular brake on obesity-driven fibrosis through regulation of purine nucleoside signalling redefines our understanding of cellular homeostasis in pathophysiology. It opens an innovative frontier for research and drug development aimed at exploiting cellular self-digestion mechanisms to prevent and treat fibrosis, a condition with limited current therapeutic options.

As this field evolves, it will be imperative to explore how lifestyle interventions, such as diet and exercise, influence autophagic activity and purinergic signalling pathways in obese individuals. Combining mechanistic insights with clinical strategies could accelerate the development of comprehensive approaches to combat the scourge of obesity-related diseases.

Piletic and colleagues’ work thus represents a landmark advancement at the intersection of metabolism, immunology, and cell biology. It exemplifies the power of integrative, mechanistic science to uncover therapeutic targets with vast clinical significance. As the scientific community delves deeper into autophagy’s role in health and disease, this study will undoubtedly serve as a foundational reference guiding future investigations.

The impact of these findings extends beyond academic curiosity—it galvanizes the biomedical field toward novel, targeted approaches for managing fibrosis and metabolic dysfunction. Harnessing autophagy to fine-tune cellular signaling and tissue remodeling may soon transition from experimental insight to clinical reality, transforming patient care for millions affected by obesity worldwide.

Article References:
Piletic, K., Kayvanjoo, A.H., Richter, F.C. et al. Autophagy acts as a brake on obesity-related fibrosis by controlling purine nucleoside signalling. Nat Commun 16, 9220 (2025). https://doi.org/10.1038/s41467-025-64266-5

Image Credits: AI Generated

Advanced glycation end products (AGEs) are harmful compounds formed when proteins or fats combine with sugars in the bloodstream. The soluble receptor for advanced glycation end products (sRAGE) plays a significant role in neutralizing these AGEs, providing a protective mechanism against the chronic inflammation they can cause. The study seeks to elucidate the levels of sRAGE in adolescents who are categorized within a spectrum of metabolic dysfunction, examining the potential for sRAGE as both a biomarker and therapeutic target.

Obesity in adolescents is not just a cosmetic concern; it’s a precursor to a host of long-term health issues, including Type 2 diabetes, cardiovascular diseases, and various metabolic syndromes. In this research, Ustkoyuncu and Kocer utilized a carefully selected participant group of adolescents diagnosed with obesity and its accompanying conditions. By assessing their serum levels of sRAGE, the authors aim to correlate these levels with markers of insulin resistance and metabolic syndrome, which is characterized by a cluster of conditions—high blood pressure, elevated blood sugar, excess body fat around the waist, and abnormal cholesterol levels.

To ground the experimental design, a rich literature review provided the necessary context, revealing a range of findings that suggest the biological importance of sRAGE. Prior studies have shown a link between decreased sRAGE levels and increased AGE accumulation, leading to heightened inflammatory responses and cellular damage. By investigating this relationship specifically in adolescents, the study offers new insights that are particularly pertinent, given the age group’s unique physiological development and vulnerability to chronic diseases later in life.

The methodology ensured that the researchers could establish a robust comparison between healthy adolescents and those affected by obesity, insulin resistance, and metabolic syndrome. Rigorous criteria were applied for the inclusion and exclusion of participants, ensuring that the data collected would yield meaningful comparisons. Blood samples were analyzed to quantify sRAGE levels, and these measurements were then juxtaposed against established indices of metabolic health, such as insulin sensitivity tests and body mass index calculations.

As the data came in, the researchers uncovered intriguing results that could have far-reaching implications. Lower levels of sRAGE were observed in adolescents suffering from obesity and insulin resistance compared to their healthy counterparts. This finding resonates with the hypothesis that impaired metabolic health is linked to the body’s inability to adequately manage toxic AGEs, ultimately compromising the protective effects typically conferred by sRAGE.

The ramifications of these findings extend beyond the laboratory. Public health officials are increasingly tasked with developing comprehensive strategies to combat childhood obesity and its sequelae. If sRAGE levels can be leveraged as an early indicator of metabolic dysfunction in adolescents, it may allow for timely interventions that can redirect the course of individual health trajectories. This presents a potential pathway for not only screening but also targeted lifestyle modifications, including diet and exercise plans that can elevate sRAGE levels.

The study also underscores the importance of understanding the underlying biological mechanisms that contribute to obesity-related conditions. Chronic inflammation, driven by high AGE levels and insufficient sRAGE, provides a vital area for further investigation. Future studies may build upon these findings by examining potential therapeutic agents that can elevate sRAGE levels, thus offering a dual benefit—improving insulin sensitivity while simultaneously mitigating the risks associated with high AGE accumulation.

In addition to the immediate health implications, the research offers insights into the societal and economic burdens of metabolic syndrome among adolescents. With healthcare costs skyrocketing due to chronic diseases stemming from obesity, early identification through biomarkers such as sRAGE could represent not just a win for affected individuals but also for the broader healthcare system.

As the global community navigates the intricacies of an obesity epidemic, this study stands as a beacon of hope. By investigating the intersection of obesity, insulin resistance, and inflammatory responses in adolescents, Ustkoyuncu and Kocer have contributed invaluable data that could influence future public health policies, clinical practices, and research directions.

The study is a call to action for researchers, healthcare providers, and policymakers alike. By prioritizing adolescent health and focusing on innovative biomarkers, we can pave the way for a healthier future generation. Groundbreaking discoveries such as these can reshape our understanding of childhood obesity, its neurological impacts, and the broader implications for society as a whole.

In conclusion, Ustkoyuncu and Kocer’s work significantly enhances our understanding of how sRAGE operates within the dynamic landscape of adolescent metabolic health. Given the rising prevalence of obesity globally, research like this is not only timely but essential in the ongoing effort to combat this epidemic effectively.

Subject of Research: Levels of soluble receptor for advanced glycation end products (sRAGE) in adolescents with obesity, insulin resistance, and metabolic syndrome.

Article Title: Soluble receptor for advanced glycation end product (sRAGE) levels in adolescents with obesity, insulin resistance and metabolic syndrome: A case-control study and the review of the literature.

Article References:

Ustkoyuncu, P.S., Kocer, D. Soluble receptor for advanced glycation end product (sRAGE) levels in adolescents with obesity, insulin resistance and metabolic syndrome: A case-control study and the review of the literature. BMC Endocr Disord 25, 209 (2025). https://doi.org/10.1186/s12902-025-02025-9

Image Credits: AI Generated

DOI: 10.1186/s12902-025-02025-9

Keywords: sRAGE, obesity, insulin resistance, metabolic syndrome, adolescents, advanced glycation end products, inflammation, biomarkers, public health.

Obesity has long been established as a major risk factor for cardiovascular disease, in particular ASCVD, which encompasses conditions such as coronary artery disease and stroke. The inflammation chronicled in adipose tissue during obesity is a critical contributor to systemic immune activation and vascular pathology. While weight reduction typically ameliorates many metabolic dysfunctions, it appears insufficient in fully extinguishing the inflammatory memory within the innate immune system. This phenomenon implicates epigenetic reprogramming—whereby immune cells undergo lasting molecular changes that reinforce heightened responsiveness—as a key mechanism underpinning residual cardiovascular risk.

Innate immune cells, including monocytes and macrophages, orchestrate frontline defense against pathogens but also regulate inflammatory processes within blood vessels. The study reveals that these cells can adopt a long-lasting hyperinflammatory phenotype following exposure to obese adipose tissue environments. This hyperresponsiveness is sustained via epigenetic modifications that prime innate immune cells for exaggerated cytokine production upon subsequent stimuli, a characteristic known as “trained immunity.” Such a state perpetuates vascular inflammation, promoting plaque formation and instability within arterial walls, which can precipitate life-threatening cardiovascular events.

Addressing this enigma, the research team conducted a translational observational case-cohort study focusing on patients undergoing metabolic bariatric surgery. By analyzing innate immune cell function and phenotype before and up to one year after surgery, researchers aimed to assess whether profound weight loss translates into normalization of immune cell behavior. Surprisingly, despite significant reductions in body weight and improvement in traditional cardiovascular risk markers, innate immune cells continued to exhibit enhanced inflammatory potential, indicating persistence of an altered immune set point.

The investigative effort also probed the role of adipose tissue itself as a modulator of immune training. Using ex vivo models, adipose tissues extracted from obese donors were shown to impose inflammatory programming on naïve immune cells. This crosstalk underscores the contribution of the adipose microenvironment in sustaining systemic inflammation and provides mechanistic insight into how immune cell memory is established and maintained. Importantly, these findings indicate that interventions targeting innate immunity alongside metabolic correction may be necessary to fully mitigate cardiovascular risk.

These revelations challenge the conventional notion that weight loss alone suffices in reversing obesity-induced cardiovascular damage. The persistence of trained immunity after bariatric surgery suggests a decoupling between metabolic health improvements and immune cell reprogramming. It further posits obesity as a trigger for long-term epigenetic remodeling within innate immunity, rendering patients vulnerable to cardiovascular events well beyond the period of active weight gain. Consequently, addressing epigenetic immune memory emerges as a novel therapeutic frontier.

Technological advances in epigenomics and immunophenotyping allowed researchers to comprehensively characterize changes in immune cell subsets and their functional responses. Monocytes isolated from post-bariatric surgery patients continued to display heightened production of pro-inflammatory cytokines such as TNF-α and IL-6 upon ex vivo stimulation. Moreover, molecular assays identified persistent epigenetic marks on gene loci associated with inflammation, substantiating the concept of trained immunity as a durable imprint rather than a transient activation state.

The study’s implications extend beyond the realm of cardiovascular disease, offering a window into the broader impact of metabolic insults on innate immune regulation. Obesity-induced immune training may contribute to increased susceptibility not only to atherogenesis but also to other chronic inflammatory diseases. Such insights provide impetus for developing targeted strategies to reverse or modulate immune cell epigenetics post-intervention, possibly through pharmacologic agents or lifestyle modifications designed to recalibrate immune responsiveness.

In clinical practice, this research advocates for a paradigm shift in post-bariatric care. Monitoring innate immune cell phenotype alongside traditional metabolic parameters could identify patients at elevated risk of ongoing vascular inflammation despite surgical success. By integrating immune profiling into risk assessment, clinicians could personalize interventions to include anti-inflammatory therapies or novel epigenetic modulators, tailored to extinguish the trained immunity imprint.

The study also opens avenues for future research aimed at deciphering the molecular triggers within obese adipose tissue that initiate immune training. Adipocytes and resident immune cells produce a complex milieu of cytokines, chemokines, and metabolic signals capable of modulating immune cell epigenomes. Understanding these interactions may reveal pivotal nodes where therapeutic intervention could prevent the establishment or perpetuation of trained immunity.

Furthermore, emerging evidence hints at the potential reversibility of trained immunity under certain conditions, albeit with variable efficacy. Investigating factors that influence the plasticity of epigenetic modifications in innate immune cells could inform combination therapies to fully restore immune homeostasis. Such approaches may prove critical to reducing residual cardiovascular risk and improving long-term outcomes for patients who have undergone bariatric surgery.

This study stands as a testament to the intricate interplay between metabolism and immunity, emphasizing that resolving obesity’s legacy on the cardiovascular system demands more than weight loss. As researchers continue to unravel the epigenetic code governing trained immunity, the prospects for innovative treatments that reconcile metabolic and inflammatory pathways grow ever more promising. Ultimately, this could lead to more effective strategies to protect millions of individuals worldwide from the enduring threats posed by obesity-related cardiovascular disease.

Subject of Research: The long-term impact of metabolic bariatric surgery on innate immune cell phenotype, function, and the persistence of trained immunity related to cardiovascular risk in obese patients.

Article Title: The long-term effect of metabolic bariatric surgery on innate immune cell phenotype and function.

Article References:
van Tuijl, J., Vreeken, D., Broeders, W. et al. The long-term effect of metabolic bariatric surgery on innate immune cell phenotype and function. Int J Obes (2025). https://doi.org/10.1038/s41366-025-01886-3

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41366-025-01886-3